On 02/03/2015 11:09 AM, Steven Charlap, MD wrote:
> I would be interested to get the group’s perspective on this product.
I’m coming to view this sort of thing as a form of hack on the incentive
structures of the investment community and public at large in order to
help create an environment in which sufficiently enormous research
funding exists to allow for the full mapping of the operation of metabolism.
At more length:
In other words this is irrelevant to life spans in the big picture.
There is no real possibility of any meaningful-in-the-grand-scheme
effects emerging from this particular research and development strategy.
It won’t assure you healthy life at 90, free from frailty and disease,
and cannot even in principle do that. It is good for raising large sums
and interest in the cataloging of mammalian cellular biochemistry. That,
however, is a distraction from the research strategies we should be
pursuing with great vigor, which are those based on damage repair rather
than messing with metabolism.